Search results
Results from the WOW.Com Content Network
This is a list of investigational sleep drugs, or drugs for the treatment of sleep disorders that are currently under development for clinical use but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses.
Somnifacient (from Latin somnus, sleep [1]), also known as sedatives or sleeping pills, is a class of medications that induces sleep. It is mainly used for treatment of insomnia. Examples of somnifacients include benzodiazepines, barbiturates and antihistamines. Around 2-6% of adults with insomnia use somnifacients to aid sleep. [2]
Main page; Contents; Current events; Random article; About Wikipedia; Contact us; Help; Learn to edit; Community portal; Recent changes; Upload file
Zolpidem tartrate, a common but potent sedative–hypnotic drug.Used for severe insomnia. Hypnotic (from Greek Hypnos, sleep [1]), or soporific drugs, commonly known as sleeping pills, are a class of (and umbrella term for) psychoactive drugs whose primary function is to induce sleep [2] (or surgical anesthesia [note 1]) and to treat insomnia (sleeplessness).
Chemical structure of the prototypical Z-drug zolpidem. Nonbenzodiazepines (/ ˌ n ɒ n ˌ b ɛ n z oʊ d aɪ ˈ æ z ɪ p iː n,-ˈ eɪ-/ [1] [2]), sometimes referred to colloquially as Z-drugs (as many of their names begin with the letter "z"), are a class of psychoactive, depressant, sedative, hypnotic, anxiolytic drugs that are benzodiazepine-like in uses, such as for treating insomnia [3 ...
The study also reports that the commonly prescribed sleep aid zolpidem — marketed under the name Ambien — may suppress those oscillations, disrupting the brain’s waste removal during sleep.
Since the release of nonbenzodiazepines, also known as z-drugs, in 1992 in response to safety concerns, individuals with insomnia and other sleep disorders have increasingly been prescribed nonbenzodiazepines (2.3% in 1993 to 13.7% of Americans in 2010), less often prescribed benzodiazepines (23.5% in 1993 to 10.8% in 2010).
[2] [4] [5] MT 1 and MT 2 receptors may be a target for the treatment of circadian and non circadian sleep disorders because of their differences in pharmacology and function within the SCN. The SCN is responsible for maintaining the 24 hour cycle which regulates many different body functions ranging from sleep to immune functions. [11]